Core Insights - IM Cannabis Corp. reported a revenue of C$54.7 million for the year ended December 31, 2025, with significant growth in Germany and a positive operating cash flow of C$4.7 million, marking a turnaround from negative cash flow in 2024 [1][6]. Financial Performance - Revenue in Germany surged over 134% to C$36.3 million, up from C$15.5 million in 2024, now representing over 66% of total Group revenue [6]. - Gross profit increased approximately 15% to C$9.7 million, driven by cost efficiencies and higher-margin sales in Germany [6]. - Cash flow from operating activities turned positive at C$4.7 million, compared to negative cash flow of C$1.1 million in 2024, indicating improved working capital management [6]. - Cash and restricted cash rose to C$3.3 million from C$0.9 million at year-end 2024, supported by strategic financings [6]. Strategic Initiatives - The company signed a non-binding letter of intent to acquire 51% of Black Axe Technologies, a Polish technology firm specializing in defense and intelligence solutions, marking its entry into the defense and homeland security technology sectors [2][11]. - This acquisition aims to target high-growth areas such as cyber drone interception, satellite intelligence, and AI analytics [2]. Operational Overview - IM Cannabis operates a medical cannabis platform in Israel and Germany, distributing cannabis to medical patients and pharmacies [3][4]. - The company leverages proprietary data and patient insights to enhance its operations and ensure quality control throughout its value chain [4].

Core Insights - HYTN Innovations Inc. has successfully released wholesale cannabis products for sale in the German market, following the completion of necessary import and quality control procedures [1][2] - The company has received a reorder for additional wholesale products, indicating strong demand and successful execution in a regulated market [2][3] - The CEO of HYTN emphasized that this milestone validates the company's GMP platform and supports its strategy to expand pharmaceutical-grade cannabis sales internationally [3] Company Overview - HYTN Innovations Inc. specializes in the formulation, manufacturing, marketing, and sale of products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids [4] - The company focuses on serving federally regulated markets by applying pharmaceutical-grade development and quality systems [4] Market Context - The successful entry into the German market is a significant commercial milestone for HYTN, reflecting its ability to navigate highly regulated international medical cannabis markets [3][2] - The acceptance of a reorder is seen as a positive indicator for building recurring international revenue channels [3]

Core Viewpoint - Tilray Medical has announced its largest portfolio expansion in Australia, reinforcing its commitment to the market and enhancing patient access to regulated medical cannabis products [1][2]. Company Commitment and Strategy - Tilray Medical has been operating in Australia for several years, supplying EU-GMP certified medical cannabis through established channels, and this expansion aligns with the rising demand in the regulated medical system [2][5]. - The President of International, Rajnish Ohri, emphasized that Australia is a strategic market for the company's international growth strategy, reflecting a long-term commitment to delivering quality cannabis products [3]. Product Portfolio Expansion - The expanded medical cannabis portfolio will include new products across multiple formats under the Redecan and Good Supply brands, enhancing treatment options for healthcare professionals and patients [4]. - The Redecan portfolio will feature medical cannabis flower, extracts, vapes, and pastilles, while Good Supply will introduce new high-potency medical cannabis flower offerings [4]. Global Presence and Market Leadership - Tilray Medical is a leading global provider of pharmaceutical-grade medical cannabis, supplying regulated markets across Europe, North America, and Australia, and is focused on safe, consistent access for patients worldwide [5][6].

Core Viewpoint - IM Cannabis Corp. (IMC) is strategically entering the defense and homeland security technology sectors by signing a non-binding letter of intent to acquire 51% of Blackaxe Technologies, a Polish company specializing in advanced defense and intelligence solutions [1][2]. Company Overview - IMC is a medical cannabis company operating in Israel and Germany, currently focused on expanding into technology-driven sectors [6]. - The company operates a medical cannabis platform that serves patients in Israel and Germany, leveraging proprietary data and patient insights [7]. Acquisition Details - The proposed acquisition of Blackaxe Technologies represents a significant strategic expansion for IMC into the defense sector, particularly in areas such as satellite intelligence, AI analytics, and counter-drone solutions [2][3]. - Blackaxe operates using advanced Israeli technologies aimed at supporting governments and defense organizations in addressing aerial and intelligence threats [3]. Market Context - The transaction is set against a backdrop of a rapidly expanding global defense and security market, driven by rising geopolitical tensions and new threats, including low-cost drones and advanced missile systems [4]. - Current conflicts in Eastern Europe and the Middle East have increased demand for satellite intelligence and counter-drone technologies, which are critical for military and homeland security agencies [4]. Transaction Conditions - The proposed transaction is subject to due diligence, execution of definitive agreements, customary closing conditions, and regulatory approvals [5].

Core Viewpoint - Vireo Growth Inc. is set to release its financial results for the fourth quarter and full fiscal year ended December 31, 2025, on March 17, 2026, before market opening [1] Group 1: Financial Results Announcement - The financial results will be disclosed on March 17, 2026, prior to market opening [1] - A conference call will be held on the same day at 8:00 a.m. ET to discuss the results [2] - Interested parties can join the conference call using specific dialing instructions and referencing a conference ID [2] Group 2: Webcast Information - A live audio webcast of the conference call will be available on the Company's Investor Relations website [3] - The webcast can be accessed through a provided link [3] Group 3: Company Overview - Vireo Growth Inc. was founded in 2014 as a pioneering medical cannabis company [4] - The company focuses on building a disciplined and execution-oriented platform within the industry [4] - Vireo aims to leverage its national portfolio while maintaining a strong local market focus [4] - The company is committed to hiring industry leaders and deploying resources to maximize value [4] - Vireo operates with a long-term mindset and a commitment to its stakeholders [4]

Core Insights - Aurora Cannabis Inc. will participate in the TD Cowen 46th Annual Health Care Conference on March 2, 2026, discussing its growth strategy and market opportunities [1] - The company has completed a transaction with Bevo Agtech Inc., enhancing its operational capabilities [1] Company Participation - Simona King, the Chief Financial Officer of Aurora, will engage in a fireside chat and one-on-one meetings with investors during the conference [1] - The discussion will cover Aurora's international leadership and the evolving global medical cannabis landscape [1] Market Position - Aurora is recognized as a global leader in medical cannabis, focusing on high-margin opportunities and a medical-first approach [1] - The company serves both medical and consumer markets across Canada, Europe, Australia, and New Zealand [1] Product and Brand Portfolio - Aurora's brand portfolio includes well-known names such as Aurora®, MedReleaf®, and Whistler Medical Marijuana Co.® [1] - The company operates GMP-certified manufacturing facilities in Canada and Germany, ensuring high-quality cannabis products [1]

Financial Data and Key Metrics Changes - Net revenue increased by 7% to CAD 94.2 million, supported by a record 12% growth in global medical cannabis revenue [16][17] - Adjusted gross margin rose by 100 basis points to 62%, with adjusted gross profit reaching CAD 55.6 million, a 6% increase [16][17] - Adjusted EBITDA was CAD 18.5 million, and adjusted net income was CAD 7.2 million, reflecting strong profitability [5][17] - Free cash flow was CAD 15.5 million, with a strong balance sheet showing CAD 154 million in cash and no cannabis business-related debt [5][17] Business Line Data and Key Metrics Changes - Medical cannabis net revenue rose by 12% to CAD 76.2 million, comprising 81% of total net revenue, compared to 77% in the prior year [17][18] - Consumer cannabis net revenue decreased by 48% to CAD 5.2 million, attributed to a strategic shift towards higher-margin global medical cannabis [18] - Plant propagation net revenue increased by 27% to CAD 11.3 million, but adjusted gross margin fell to 16% due to increased costs [18][19] Market Data and Key Metrics Changes - International medical cannabis revenue grew by 17%, with Germany being a primary driver of this growth [4][17] - The Australian market is projected to become a AUD 1 billion opportunity, with efforts to shift sales towards premium products [11] - In Poland, the company maintained its number one position in market share, benefiting from increased annual import limits [12][13] Company Strategy and Development Direction - The company is focusing on exiting select markets within the lower Canadian consumer cannabis segment to prioritize higher-margin global medical cannabis [7][15] - A divestiture of the lower-margin plant propagation operations is planned to enhance profitability and streamline operations [7][39] - The company aims to expand its leadership in global medical cannabis, reinforcing its presence in Canada, Europe, Australia, and New Zealand [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of the global medical cannabis market, projected to surpass $9 billion [23] - The company is adapting to regulatory changes in markets like Germany and Poland, ensuring continued access to high-quality medical cannabis [10][42] - Future guidance anticipates annual global medical cannabis net revenue to increase to between CAD 269 million and CAD 281 million, driven by 10%-15% growth [21][22] Other Important Information - The company filed a prospectus supplement for a new At-the-Market equity program, allowing the issuance of up to $100 million in common shares for strategic purposes [8] - The company maintains a strong competitive position due to its regulatory certifications and GMP manufacturing capabilities [6][10] Q&A Session Summary Question: Follow-up on the select market exit in Canada - Management indicated that exiting these markets will be beneficial to overall financial results, reallocating resources to higher-margin international markets [25][26] Question: Impact of premiumization strategy in Australia - Management stated that the shift towards premium products is not disruptive and is expected to enhance margins [29][30] Question: Strategic decision to exit plant propagation - The focus remains on global medical cannabis, with divestiture seen as a way to allocate resources more effectively [37][39] Question: Clarification on global medical cannabis revenue guidance - Management clarified that the guidance reflects total revenue, including the impact of the divestiture of Bevo [47][48] Question: Supply chain and cultivation capacity - Management confirmed that the majority of products sold are produced in-house, with a focus on maintaining GMP standards [76][78]

INVESTOR PRESENTATION FY26 Q3 February 2026 Disclaimer CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information contained in this presentation constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "in ...

Core Insights - The publication reports significant improvements in pain-related outcomes, mental health measures, and quality of life among chronic pain patients using physician-authorized medical cannabis, as detailed in a study published in the Canadian Journal of Pain [1][6]. Study Overview - The study is a prospective, observational analysis evaluating patient-reported outcomes among chronic pain patients receiving medical cannabis under healthcare provider supervision, supported by multiple clinicians and medical institutions across Canada [2][3]. - The study was led by Dr. Hance Clarke at the University Health Network (UHN) and utilized the MyMedi.ca platform for data collection and patient support [1][8]. Study Results - Statistically significant improvements were observed in pain interference and pain intensity, as well as in anxiety, depressive symptoms, and overall quality of life over a 24-week follow-up period [5]. - Although the magnitude of change did not meet established minimal clinically important difference thresholds, the directional improvements align with existing literature on medical cannabis [5]. Scientific and Clinical Significance - The study represents a milestone for Avicanna, emphasizing the importance of high-quality, prospective real-world data in complementing randomized clinical trials and informing clinical practice [7]. - As regulatory frameworks evolve, physician-supervised models and rigorous data generation will be crucial for advancing cannabinoid-based medicines [7]. Ongoing Research and Development - The MCRWE study is ongoing, with continued patient recruitment across seven Canadian provinces, focusing on various outcomes associated with medical cannabis use [9]. - Avicanna is involved in providing the necessary infrastructure for large-scale real-world evidence research, ensuring that clinical decision-making and patient care remain unaffected [8]. Company Background - Avicanna is a biopharmaceutical company dedicated to the development and commercialization of cannabinoid-based products for medical and pharmaceutical markets, with over thirty proprietary products [11]. - The company has established a scientific platform that includes R&D and clinical development, supporting its commercial operations [11].

Core Viewpoint - IM Cannabis Corp. has raised a total of US$2,171,660.40 in debt financing to address its liquidity needs, with two separate note purchase agreements executed with a third-party lender [1][10]. Group 1: First Note Financing - The first note issued to the lender amounts to US$1,538,749, after a 10% original issuance discount [2]. - This note carries an interest rate of 8% per annum, which increases to 14% upon an event of default, and has a maturity of 18 months [3]. - Repayment of the principal and accrued interest will occur in ten equal monthly installments after the maturity date, with the option for early repayment subject to lender consent [4]. - The first note is convertible into common shares at a price of US$1.47 or 90% of the lowest daily volume-weighted average price during the preceding 20 trading days, with a floor price of US$0.29 [5]. - The company issued 228,150 common share purchase warrants to the lender, allowing the purchase of shares at C$3.45 for five years [6]. - Approximately US$500,000 of the proceeds were used to repay existing creditors, enhancing financial flexibility [7]. Group 2: Second Note Financing - The second note issued to the lender totals US$632,911.50, also after a 10% original issuance discount [10]. - Similar to the first note, it bears an 8% interest rate, increasing to 14% upon default, and matures in 18 months [11]. - Repayment terms mirror those of the first note, with ten equal monthly installments post-maturity and conditions for early repayment [12]. - The second note is convertible into common shares at a price of US$1.38 or 90% of the lowest daily VWAP, with a floor price of US$0.275 [13]. - The company issued 93,671 common share purchase warrants to the lender at the same price of C$3.45 for five years [14]. - Similar to the first note, US$500,000 of the proceeds were allocated to repay creditors and improve financial flexibility [15]. Group 3: Regulatory and Compliance - IM Cannabis Corp. is required to file a registration statement with the SEC covering the resale of common shares from both notes within 30 trading days of the respective purchase agreements [8][16]. - All securities issued are subject to a hold period of four months and one day from the issuance date [9][17]. Group 4: Company Overview - IM Cannabis Corp. is a leading medical cannabis company operating in Israel and Germany, focusing on sustainable and profitable growth in these markets [18]. - The company utilizes a data-driven approach and a globally sourced supply chain to enhance its operations [18]. - It operates through subsidiaries that import and distribute cannabis, as well as retail pharmacies and online platforms in Israel, and distributes cannabis to pharmacies in Germany [19].